Voices
FDA
Alexandra Snyder/LinkedIn

SITC, FDA, and AACR Workshop on Novel Endpoints in Cancer Drug Development

Society for Immunotherapy of Cancer (SITC) shared a post on LinkedIn:

“Society for Immunotherapy of Cancer (SITC) is excited to join the FDA and the American Association for Cancer Research today to collaborate on a workshop to explore considerations for the development and application of novel endpoints in oncology drug development.

Thank you to Alexandra Snyder, MD, representing SITC, for co-chairing this event.”

SITC, FDA, and AACR Workshop on Novel Endpoints in Cancer Drug Development

More posts featuring SITC.

Alexandra Snyder cancer OncoDaily Oncology SITC Society for Immunotherapy of Cancer